Emtora Biosciences
San Antonio
About Emtora Biosciences
Emtora Biosciences is a life science company that commercializes a new formulation of an immunosuppressant as a prostate cancer drug. The company developing a novel formulation of rapamycin, eRapa for use in preventing the onset and recurrence of cancer. It manufactures a drug to slow the aging process and its efficacy in treating age-related diseases. The eRapa is the only pharmaceutical agent to demonstrate significantly increased healthspan and lifespan in rodent models, and Science, Nature, and Time magazines proclaimed the discovery of a special formulation of rapamycin to extend one’s life and health span among the most significant and exciting scientific breakthroughs of 2009.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $26.8M
- Funding stage: Early Stage Venture
- Last round: Grant (May 2025)
- Website: emtorabio.com
- Phone: (210) 381-2486
Industries & Categories
Biotechnology, Health Care, Life Science, Manufacturing, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/emtora-biosciences-7130 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.